Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AC Immune
AC Immune identifies lead compounds for Alzheimer disease treatment
April 8th, 2006
AC Immune, a Swiss biotech company developing innovative therapies against Alzheimer disease, has identified lead drug candidates for clinical development for both active and passive immunotherapies. Both therapeutic approaches have shown significant improvement of the memory function in animal studies. AC Immune's proprietary therapeutic approach against Alzheimer disease has resulted in the development of a vaccine as well as a passive immunotherapy with a selected monoclonal antibody which was highly active in animal models for Alzheimer disease. Both treatments significantly improved the memory capacity. The results also...
Source: Law & Health Weekly (2006-04-08)
|
